DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, ...

A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...